GL1X · GenesisL1 explorer

MolNFT v1 · #18457 · protein

Crystallographic analysis of transition-state mimics bound to penicillopepsin: phosphorus-containing peptide analogues

1PPM: “Crystallographic analysis of transition-state mimics bound to penicillopepsin: phosphorus-containing peptide…”. X-ray diffraction, 4 ligands (0P1, MAN, ARA), 1 pocket (best druggability 0.61). MolNFT v1 #18457 on GenesisL1: 3D…

PDB
1PPM
Type
protein
Length
323 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Penicillopepsin
EC
3.4.23.20
UniProt
P00798
Ligands
0P1, MAN, ARA, SO4
Pockets
1 · best druggability 0.61

Structure

x-ray diffraction · 1 distinct chain · 14% helix, 48% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
EPenicillopepsin (EC 3.4.23.20)protein32314% helix, 48% strandP00798

Ligands and binding sites

  • 0P1 · N-[(benzyloxy)carbonyl]-L-alanyl-N-{(1S)-1-[(R)-[(1R)-1-benzyl-2-methoxy-2-oxoethoxy](hydroxy)phosphoryl]-3-methylbutyl }-L-alaninamide · ligand · chains E
  • MAN · alpha-D-mannopyranose · sugar · chains E
  • ARA · alpha-L-arabinopyranose · sugar · chains E
  • SO4 · Sulfate ion · ion · chains E

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13410.610.77470P1

Modifications

Observed in the structure: 2 glycan, 1 disulfide (O-glycosylation, disulfide).

Compared structures

  • 1PPM · Crystallographic analysis of transition-state mimics bound to penicillopepsin… · the same entry in another collection · chain E against E, TM-score 1.00
  • P00798 · AlphaFold monomer V2.0 prediction for penicillopepsin-1 (P00798) · a predicted model of the same protein · chain E against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.